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1.1. Background 
Breast cancer is the second most common cancer in adults and the most frequent cancer 
diagnosed in women.1 However, breast cancer mortality rates are higher in low and middle 
income countries (LMICs).2,3 In South Africa, Breast cancer accounts for more than 20% of 
cancers diagnosed in women.1 One of the biggest challenges of breast cancer management in 
LMICs is lack of access to new and improved treatment and staging technologies. Staging is 
defined as an assessment of tumour spread in an untreated patient with confirmed cancer.4 
Staging is also important for disease prognosis as well as accurate inter-institutional comparison 
of survival and mortality. 
 
Breast cancer prognosis has improved globally over the last decade nearing 80% at 5 years, 
owing to the improvement in early detection and treatment: Survival rate decreases to less than 
60% and 20% in cases of locally advanced breast cancer and metastatic disease, respectively.5 
For accurate inter-institutional comparison of survival and mortality, accurate standardized 
staging is important. 
 
In LMICs, breast cancer patients tend to present late (especially in the public sector), usually 
with locally advanced or metastatic disease. There is no consensus on the definition of ‘locally 
advanced breast cancer (LABC)’,6 but most commonly this term refers to clinical stage III 
disease, which is a heterogeneous group of advanced primary and/or nodal disease without 
clinically evident systemic metastases(table 2). Approximately 40% of patients with LABC will 
develop metastasis within five years post treatment.7, 8  
 
Neo-adjuvant chemotherapy (NACT) is the standard of care in LABC,9 and is increasingly used 
in patients with larger operable breast cancer and/or with axillary lymph node metastases.10,11 
Administration of NACT follows radiological exclusion of metastasis. Presence of distant 
metastases is the single most important prognostic factor in patients with breast cancer, and 
plays a critical role in determination of therapy.12 The presence of non-regional nodal 
(ipsilateral) metastases in breast cancer patients immediately excludes them from radical 
treatment,6,13,14 which consists of sequential combination of NACT, radical breast surgery, and 
radiotherapy with or without endocrine therapy. Patients with metastatic breast cancer receive 
palliative treatment to improve quality of life, consisting of either endocrine therapy or single 
agent chemotherapy in the majority of patients. Hence, it is crucial to accurately stage LABC 
at first presentation. 
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NACT for LABC consists of at least six cycles of combination chemotherapy and, according 
to the European Society for Medical Oncology (ESMO),15 and St. Gallen International Expert 
Consensus, it should include an anthracycline and a taxane.16 Therefore accurate staging at 
diagnosis is crucial to ensure that appropriate treatment is offered to patients, and to prevent the 
unnecessary overtreatment of patients harbouring metastases.   
 
LABC require complete staging before initiation of therapy. Assessment of metastasis via 
conventional imaging (CI) ideally include whole body CT and bone scans, but at GSH we use 
a chest  radiograph, an ultrasound scan of the abdomen (targeting the 3 common areas for breast 
metastasis), and a bone scan at due to resource constraints and long waiting times for the whole 
body CT scan. However, several studies demonstrate the sensitivity of CI to be lower than 
60%.7,10,12 When used appropriately in oncology, PET/CT can provide useful clinical 
information and has been postulated to lead to significant cost savings in patient 
management(such as avoiding expensive intervention; surgery, chemotherapy, radiotherapy). 
17, 18 Strong evidence has demonstrated superior diagnostic accuracy of PET-CT in comparison 
to conventional imaging in staging and restaging of most cancers.19 The use of 18F-FDG 
PET/CT for disease staging of patients with locally advanced breast cancer may improve 
diagnostic sensitivity,20 However, we’re still unsure of the diagnostic superiority of 18F-FDG 
PET/CT over CI in LABC. 
 
Previously, Schirrmeister et al(2001) found as high as 20% false-negative rate for detection of 
lymph node metastases in breast cancer when using 18F-FDG PET,21 but this was a 
heterogeneous group of participants that included early breast cancer, and  also included 
invasive lobular carcinoma that is known to be poorly 18F-FDG PET avid. Research suggests 
that the merit of this technology for screening and work-up is questionable because no large 
prospective studies have been done, and the high false negative sclerotic bone lesions on 18F-
FDG PET, but has superior detection rates once combined with CT.19 In addition, although 
some studies have compared whole-body PET/PET-CT with conventional imaging, most of the 
results have been criticised:7 The limitation of many of these studies is they were retrospective, 
and were without histologic confirmation of suspected metastases.5,22 In addition, very few 
prospective studies have been conducted in the developed world,10,23 limited by their bias for 
breast cancer recurrence or metastatic disease,24 and lack of histopathological stratification.25  
 
Nevertheless, the use of 18F-FDG-PET/CT for staging in a selected group of high-risk breast 
cancer patients has been shown to be accurate in identifying metastases.15,16,26,27 Therefore, 
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based on this evidence, as well as recommendations from the National Comprehensive Cancer 
network (NCCN),13,14 and ESMO15, 18F-FDG PET/CT was introduced for the staging of 
invasive ductal carcinoma(IDC) LABC at Groote Schuur Hospital (GSH) since May 2015. The 
South African College of Nuclear Physicians (CNP) recommends the use of 18F-FDG PET/CT 
as an adjunct to CI when studies are equivocal in LABC staging or metastatic breast cancer.28 
 
Accurate detection of metastases can reduce the number of radical treatments and alter course 
of disease. On the other hand, failure to detect metastases can lead to poor quality of life. Poor 
inter-institution concordance of breast cancer staging implies inconsistent diagnosis and 
treatment, and may be reflected in higher mortality in institutions where it is systematically 
inaccurately staged.11 No studies have investigated whether the use of 18F-FDG PET/CT in IDC 
LABC at Groote Schuur Hospital is appropriate. Furthermore, the cost of breast cancer 
treatment, as well as whole-body 18F-FDG PET/CT for staging purposes, may be prohibitive in 
health care systems with limited resources. The initial 18F-FDG PET/CT recommendation in 
breast cancer staging was for multifocal disease or suspected disease recurrence.29 This study 
may provide to evidence to oncology treatment teams on the most appropriate staging modality 
in IDC LABC staging in the local context. 
 
1.2. Aim 
To assess the difference in the sensitivity in detecting metastases between whole-body 18F-FDG 
PET/CT and conventional imaging (CI) for staging in participants with locally advanced 
irresectable invasive ductal carcinoma (IDC) of the breast treated at Groote Schuur Hospital.  
 
1.3. Hypothesis 
18F-FDG PET/CT has a greater sensitivity than conventional imaging with CXR, bone scan and 
abdominal ultrasound in locally advanced irresectable invasive ductal carcinoma of the breast. 
 
1.4. Objectives 
1. To compare the potential differences in the detection rate of distant metastases in locally 
advanced breast cancer between whole-body 18F-FDG PET/CT PET/CT and 
conventional imaging modalities used at GSH. 
2. To establish if whole-body 18F-FDG PET/CT should replace CI at GSH for the staging 
of IDC locally advanced breast cancer. 
3. To describe the clinical impact on patient management of the study outcomes. 
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4. To determine 18F-FDG PET/CT specificity in isolated lymph nodes beyond normal 
breast cancer lymphatic drainage. 
 
1.5. Methods 
1.5.1. Design: 
This will be a prospective study of forty (40) participants diagnosed with irresectable locally 
advanced breast cancer at GSH.  Participants will be staged with CI (CXR, Abdominal 
ultrasound and bone scan) in addition to 18F-FDG PET/CT.  Participants found to have isolated 
mediastinal lymph nodes will have cytological confirmation performed.  The detection rate of 
metastases between 18F-FDG PET/CT and CI will then be compared. 
 
1.5.2. Sample: 
The number of study participants required was derived using the chi-square test.  A detection 
rate of 60% for PET/CT and 18% for CI for clinical T3/T4 disease, irrespective of nodal status, 
was estimated in the breast clinic at Groote Schuur Hospital. 
 
1.5.2.1. Inclusion Criteria: 
1. Newly diagnosed IDC LABC found to irresectable to upfront surgery (Appendix 2). 
2. No previous malignancies or treatment thereof, and not known to GSH Oncology unit. 
3. Performance status and co-morbidities; ECOG 0-2, participants must be candidates to 
undergo radical treatment. 
4. Histology: infiltrating ductal carcinoma (IDC).22 
 
1.5.2.2. Exclusion Criteria: 
1. Early breast cancer (stage I and II) 
2. Pregnant or lactating participants 
3. Breast cancer recurrence 
4. HIV/AIDS positive participants  
5. Confirmed active tuberculosis, and/or on treatment 
6. Age below 30 years,30 for radiation protection considerations 
7. Male gender 
8. Diabetic participant 
9. Surgery in last 3 months 
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1.5.3. Procedures: 
Participants will be identified at the walk-in breast cancer clinic at SOPD GSH. Suspected 
LABC participants will be assessed by a surgical consultant. Participants will undergo routine 
examination, FNAC (fine needle aspiration cytology) and Tru-cut biopsy, as per current 
protocol guidelines. 
 
Participants who meet the eligibility criteria will be identified by the oncologist (registrar) at 
SOPD and consented for the study. CI (mammogram, chest x-ray, abdominal ultra-sound scan, 
bone scan) in addition to PET/CT will be requested.  CI and PET/CT will be performed within 
a three week period, estimated from the turn-around time for LABC patients in our department. 
The study will not interfere with standard of care, all LABC would have PET/CT done as per 
GSH protocol. No additional slots for scans will be requested outside the standard procedure.  
Two qualified Nuclear medicine physicians will read the PET and the bone scans separately. 
The CT part of the 18F-FDG PET/CT and the CI will be read by a qualified radiologist. The 
radiologist reporting the CI and the nuclear medicine physician reporting the PET/CT will be 
blinded to the findings of each other.  
 
1.5.3.1. PET/CT 
18F-FDG PET CT imaging will be done using a GEMINI TF Big Bore PHILIPS whole-body 
scanner. Participants will be prepared, injected and imaged in accordance with the FDG 
PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 (2015). 
 
Propranolol 20mg will be administered orally 30 minutes prior to 18F-FDG injection to each 
participant to decrease the amount of brown fat uptake. Participants in whom propranolol is 
contraindicated will not receive it and the reasons clearly documented. The participants will be 
positioned supine in the PET CT scanner and acquisition from base of skull to mid-thigh will 
be started 60 minutes after tracer injection. Images will be acquired in 3- dimensional mode and 
reconstructed with attenuation correction using a 5-node quad core CPU computer cluster 
provided by PHILIPS. For whole body PET a relaxed list mode ordered subsets expectation 
maximization algorithm (BLOB-OS), with spherically symmetric basis functions on a body 
centred cubic grid to represent the emission object will be used. Images will be viewed with 
Hermes Hybrid Viewer PDR v.2.2C.21 and interpreted by a Nuclear Medicine Physician and 
Radiologist. Low dose uncontracted CT will be performed. The CT portion of PET/CT provides 
the anatomic information useful for accurate interpretation of PET signal. It also provides a 
map used for attenuation correction of PET images.  
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The FDG PET CT images will be interpreted by a Nuclear Medicine Physician and a 
Radiologist who are blinded to other imaging results and clinicopathological findings other than 
the presence of breast cancer. All sites of abnormal 18F FDG uptake (areas that do not conform 
to normal physiological 18 F FDG uptake) will be listed. Each area will be scored as 1 = 
negative for metastasis; 2 = equivocal for metastasis; and, 3 = consistent with metastasis. 
 
Standard uptake values for each area will be calculated using the following formula SUVw =A 
× W/D × 1000 g/c where SUVw= Normalization to body Weight, A= Activity Concentration in 
Becquerel/cubic centimetres (Bq/cc), W= Participant weight in kg and D= Injected dose in Bq 
decay corrected. The SUVmax defined as the highest SUV in the pixel for within the region of 
interest (ROI) will be recorded.  
 
1.5.3.2. Bone Scintigraphy 
All participants will be scanned on a Siemen’s eCam Signature series dual head gamma camera 
(200^). If a SPECT CT is required, the participant will be transferred to a Symbia hybrid 
SPECT-CT for the SPECT CT acquisition. Examinations will be processed and viewed on the 
HERMES physicians’ workstations. 
 
Participants will be prepared, injected and imaged according to SNM guideline procedure 
guidelines31. Each participant will be injected with 740 MBq-1110 MBq of Technetium-99m-
methylene diphosphonate (MDP) (according to the body weight). Planar images will be 
acquired using a low energy high-resolution collimator. 
 
SPECT images will be obtained using a 128 x 128 matrix with 25 seconds per step acquiring 
64 projections with 180degree rotation for each gamma camera head. Images will be 
reconstructed using Flash 3D ordered subset expectation maximization (OSEM) iterative 
reconstruction algorithm in 4 subsets and 8 iterations. 
 
CT images will be acquired using a low dose protocol without intravenous contrast 
administration. The low dose CT parameters will be: 2.5-30mAs, 120 kV, slice thickness of 
1.25-5mm and pitch of 1.5. Images will be reconstructed using high-resolution reconstruction 
algorithms (B08s kernel). 
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The planar images will be interpreted by a Nuclear Medicine Physician, SPECT/CT, if acquired, 
will be read together with a radiologist, both the  Nuclear Medicine Physician and Radiologist 
are blinded to other imaging results and clinicopathological findings other than the presence of 
breast cancer. All sites of abnormal 99mTc- MDP uptake (areas that do not conform to normal 
physiological uptake will be listed.  Each area will be scored as 1 = negative for metastasis; 2 
= equivocal for metastasis; and, 3 = consistent with metastasis. 
 
1.5.3.3. Abdominal Ultrasound scan (USS) 
USS studies will be performed according to routine practice using the Toshiba Nemeo XGI 
machine, with a convex (3-6MHz) transducer and when necessary a linear (7-12 MHz) 
transducer as well as Doppler imaging. USS of the liver will be performed with conventional 
B-mode and metastases will be identified according to conventional imaging criteria. USS 
findings will be recorded by number, size, and location of the lesions. Each lesion will be scored 
as 1 = negative; 2 = equivocal; and 3 = consistent with metastases. 
 
1.5.3.4. Chest X-ray (CXR) 
CXR will be performed according to routine practice at our institution: PA and lateral views 
(125 Kv and 2-5 mas) to identify metastases in the lung, mediastinum, or visualized thoracic 
spine. CXR findings will be recorded as 1 = nodules/mass lesion either infective or suspicious 
for metastases; 2 = opacification, fibrosis, of nodules/mass; 3 = septal thickening suggestive of 
lymphangitis carcinomatosis; and, 4 = mediastinal, supraclavicular, or hilar nodes. 
 
Chest X-rays that are reported as suspicious for metastases will be subjected to diagnostic CT 
scans, as per standard of care. Should participants be found to have isolated metastases on 18F-
FDG PET/CT, they will be subjected to biopsy for histologic confirmation21, as per standard of 
care. After the staging investigations, participants will be treated as per current departmental 
guidelines.   
 
1.5.3.5. Biopsy of isolated metastases on FDG PET CT 
Biopsy will be performed using endobronchial ultrasound (EBUS)-guided transbronchial 
needle aspiration is a technique (TBNA).  EBUS is a technique that uses ultrasound along with 
bronchoscope to visualize airway wall and structures adjacent to it. The clinical application and 
diagnostic benefit of EBUS have been established in many studies. EBUS has been incorporated 
into routine practice in many centres because of its high diagnostic informative value and low 
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risk.32, 33 It may replace more invasive methods for staging lung cancer or for evaluating 
mediastinal lymphadenopathy and lesions in the future.  
 
In the proposed study we will use EBUS-TBNA to access and cytologically confirm the 
presence of invasive ductal cell breast cancer in intrathoracic nodes that show increased activity 
on 18F-FDG PET scanning. These lesions will be identified following a combined reading of 
the CT and PET scan by both qualified radiologists and nuclear medicine physicians. In 
conjunction with the pulmonologist a procedure will be planned. 
 
EBUS will be performed under procedural sedation using both fentanyl and midazolam. 
Participants will be nil per os (NPO) for at least 6 hours prior to the procedure. Participants will 
be positioned supine with operator standing on head end of bed: The bronchoscopist should 
have clear view of monitor. The monitoring devices will be placed onto the patient, 
supplemental oxygen will be administered by nasal cannula, and intravenous access established 
before starting the procedure. Participant’s eyes will be covered to prevent splashing the normal 
saline, secretion, or blood into them. Curved probe-EBUS will be performed orally, as 
ultrasound probe in it prevents using nasal route. Once in the airways, a syringe filled with 
sterile water will be attached to the balloon channel of the scope and the balloon filled with 
water to achieve contact with the airways. Lymph nodes that show increased activity on 18F-
FDG PET scanning will be identified with its typical sonographic appearance. Aspirated 
specimen will be smeared onto glass slides and fixed so that a cytopathologist can evaluate the 
specimen. Histological cores (if obtained) will be fixed with formalin and sent to the pathology 
department for cell block.  
 
Continuous monitoring of cardiac rhythm, heart rate, respiratory rate, oxygen saturation, and 
blood pressure will be done after the procedure until the effects of sedation and upper airway 
anaesthesia have resolved. Eating and drinking can be resumed once the gag reflex returns. A 
chest radiograph will be performed only if clinically indicated. Outpatients must have stable 
vital signs, be alert and oriented with baseline ambulation status before discharge. 
 
1.5.4. Data collection: 
The following data will be prospectively collected: Age; co-morbidities; clinical stage (AJCC 
TNM staging system); histopathologic subtype; immunohistochemistry markers (ER/PR and 
HER2 status); B-DISH results in participants found to have equivocal HER2 results on IHC; 
Ki-67 in participants with luminal disease; CI results (including mammogram [BIRADS score 
11 
 
1-6, presence of lymph nodes], breast ultrasound scan if done, CXR, bone scan, abdominal 
ultrasound, CT chest if needed); PET/CT results; liver function blood test results; time interval 
between the last CI test and the PET/CT; waiting period from diagnosis to completion of CI vs 
PET/CT; if metastases were pathologically confirmed; number of metastatic sites detected by 
both techniques; site of metastases; presence of regional (lymph node) metastases; and, 
treatment plan from the multi-disciplinary team. 
 
1.5.5. Data analysis 
The primary end point of this study is the sensitivity difference between 18F-FDG PET/CT and 
CI in the detection of metastases in irresectable IDC LABC.  Estimated specificity will be 
calculated for the biopsies of the 18F-FDG PET/CT isolated metastases. The number of study 
participants required was derived using the chi-square test.  A detection rate of 60% for PET/CT 
and 18% for CI for clinical T3/T4 disease, irrespective of nodal status, was estimated in the 
breast clinic at Groote Schuur Hospital. Assuming a 40% difference in the sensitivity between 
18F-FDG PET/CT and CI groups, minimum of 38 participants will be required for the final 
analysis with 95% statistical power to detect sensitivity difference using a chi-square test at an 
alpha level of 5%. Data will be collected and stored on a Microsoft excel spreadsheet. Stata and 
R will be the statistical software employed for the analysis. 
 
1.6. Ethical considerations 
The clinical standard of care management of the participant will not be affected by the study. 
According to current standard departmental clinical protocols, IDC LABC patients are staged 
with 18F-FDG PET/CT and are managed radically or palliatively accordingly. While CI is used 
in early breast cancer as standard of care at GSH, it is not employed in LABC. 
 
In this prospective study, in addition to 18F-FDG PET/CT which is GSH standard of care, 
participants will be exposed to CI, which will be employed specifically for research purposes .  
This poses potentially a small increase in risk from the excess radiation exposure from the bone 
scan. The total radiation dose to the participant will be taken into account in accordance with 
the ALARA (as low as reasonably acceptable) principles of Radiation protection.34  There is no 
risk from an abdominal ultrasound.  From the table below, the excess radiation received will be 
approximately 3-6 mSv.  
 
Cancer induction is both dose and age related: the higher the dose the higher the likelihood of 
cancer induction, and exposure to radiation before the age of 30 increases the induction of 
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second cancers.30 Effective doses are the parameters used for benefit/risk assessment in the 
approximation of the detriment of ionization radiation, and compares the detriment from cancer 
and hereditary effects (Stochastic effects). The risk for leukaemia and solid tumours (especially 
breast and lung cancer) induction is 1.7%/Sv and 0.275%/Sv respectively, if exposed before the 
age of 30, affected too by smoking, with a risk reduction in later life exposure. The above added 
dose (3-6 mSv) bone scan predisposes one to cancer induction by under 0.05% (Appendix 1).35  
The risk associated with a biopsy, in the case of usual isolated metastases, must be weighed 
against the benefit of obtaining a definitive stage and appropriate treatment.  The main risk from 
biopsy is bleeding and post procedural pain in the participant. The gold standard of confirming 
an isolated suspicious metastasis is to have tissue diagnosis by biopsy:  Some studies have 
shown the misdiagnosis of metastasis in indolent infectious state,36,37 and Cape Town 
population is highly endemic for Tuberculosis.38 The biopsy result will give a definite answer 
as to whether the participant should be managed radically or palliatively. A separate consent 
will be sought for the biopsy, and risks explained in full. As discussed above, this difference 
has significant implications for the participant and the benefit of a biopsy far outweighs the 
risks that are associated with it. The benefit to the participant will be that the extra test will add 
to the positive and negative predictive value of their staging. 
 
The workflow in Nuclear medicine and radiology will not be affected by this study. Imaging 
slots will be booked through the routinely used 2-week slots at GSH in time for the MDT: All 
investigations, nuclear medicine and radiology, will be arranged according to normal 
scheduling, with no additional slots requested. The study will not at any point disadvantage 
non-participating patients with LABC who are investigated with 18F-FDG PET/CT as per 
standard of care. 
 
Informed consent will be sought from the participant for study participation by non-coercive 
methods. It is understood that diagnosis of cancer leaves one vulnerable, and are at risk of 
making rushed decisions towards information that seems to offer a better disease outcomes: 
The radiation oncology registrar taking consent will make it clear to the potential participant 
that taking part in the study does not confer therapeutic gain, nor change the current standard 
of care. We endure to make it clear that this study will not delay or derail standard of care for 
the participant, but may be of benefit for future patients.  Consent will specifically explain the 
extra radiation dose the participant will receive.  The imaging modalities will be at no added 
cost to the participant and any transport costs associated with extra hospital visits will be 
covered by the study. 
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Electronic information will be stored on a password protected laptop as well as a password 
protected cloud server. The participants will be informed that the results of this study will be 
used for research, and the department will store the anonymised information for future research. 
The cost of this study will be absorbed by the department of radiation oncology, Groote Schuur 
Hospital.  
 
1.7. Resources 
Published journal articles; PubMed; Google Scholar; University of Cape Town FHS library 
databases; EBSCOhost; Clinicalkey; Web of Science; Africa-Wide; EndNote X7; Microsoft 
Excel; and, Stata. 
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1.9. Appendices  
 
1.9.1. Appendix 1: Effective Doses per modality 
 
DIAGNOSTIC IMAGING MODALITY RADIATION EFFECTIVE DOSE (mSv)34, 
39, 40 
Mammogram 0.4 (0.10-0.60) 
Chest x-ray 0.1 (0.04-0.24) 
Chest CT scan 7.0 (4.0-18.0) 
Ultra-sound scan 0 
Bone Scan 3-6.3 (0.0057mSv/MBq) 
PET/CT Scan 4-5.6 (0.02mSv/MBq) 
TOTAL EXPECTED 
DOSE/PARTICIPANT 
10-30 
 
1.9.2. Appendix 2: Breast Cancer TNM Staging4 
 
Nodal 
status/Metastasis 
T stage 
T1 T2 T3 T4 
N0 I IIa IIa IIIb 
N1 IIb IIb IIIa IIIb 
N2 IIIa IIIa IIIa IIIb 
N3 IIIc IIIc IIIc IIIc 
M1 IV IV IV IV 
Shaded boxes constitute the heterogeneous group of clinically-determined LABC. 
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1.9.3. Appendix 3: Study consent form 
 
 
PARTICPANT INFORMATION SHEET AND CONSENT FORM 
 
INVESTIGATION OF BREAST CANCER IMAGING: A COMPARISON OF PET/CT 
SCAN AND CONVENTIONAL IMAGING 
 
Investigators:  Dr Paul Chilwesa, Radiation Oncology, Groote Schuur Hospital 
We would like to invite you to take part in a research study. Research is a way of finding out 
new knowledge that may help us develop better treatments for patients in the future. 
You are attending Groote Schuur Hospital breast cancer clinic for treatment of your breast 
cancer. As part of your care, you will undergo some scans to assess whether your cancer has 
spread. This is important because it allows doctors to decide on the best treatment for you.  
We are still uncertain which type of scan is the best to use, so we would like to scan you for 
research purposes using different machines and techniques so that we can compare them. As 
part of your standard care, you would receive a PET/CT scan. A PET/CT is a special type of 
scan that uses a radioactive dye that may allow the identification of tumour cells in different 
places in your body if the tumour has spread. For research purposes, we would like to request 
that you agree to have some additional scans, namely, a chest x-ray, an ultrasound scan, a 
bone scan and a CT scan.  
 
What will the study involve? 
PET/CT 
This scan, which is part of your routine care, will take place at Tygerberg Hospital so 
transport will be provided to take you there. The procedure will involve injection of a 
radioactive dye into your arm and your whole body will be scanned using the PET/CT 
machine. This may take between 5 and 40 minutes. If the PET/CT reveals images that are not 
clear, we may need to take a biopsy, which involves taking a small sample using a needle in 
an area shown on the scan to test if tumour is present. Such biopsies would also be part of 
your standard care if required. 
 
Bone scan 
A bone scan is a nuclear imaging procedure. In nuclear imaging, tiny amounts of radioactive 
dye (tracers) are injected into a vein and taken up in varying amounts at different sites in the 
body. Areas of the body where cells and tissues are repairing themselves most actively take 
up the largest amounts of tracer. Nuclear images highlight these areas, suggesting the 
presence of abnormalities associated with disease, such as cancer, or injury. A bone scan 
includes both an injection and the actual scan. 
 
Chest x-ray 
Chest x-ray is a non-invasive procedure, with invisible rays directed at your chest, with a 
digital image taken. You will be asked to keep still when the image is taken. It is a short 
procedure, lasting not longer than 5 minutes. 
Ultrasound scan 
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The ultrasound image is created by first transmitting sound waves into the body and then 
interpreting the intensity of the reflected echoes.  This is achieved using a hand held probe 
which contacts the body via a water based gel. 
 
CT scan 
The CT scanner looks like a giant thick ring. Within the wall of the scanner there is an X-ray 
source. Opposite the X-ray source, on the other side of the ring, are X-ray detectors. You lie 
on a couch which slides into the centre of the ring until the part of the body to be scanned is 
within the ring. The X-ray machine within the ring rotates around your body. As it rotates 
around, the X-ray machine emits thin beams of X-rays through your body, which are detected 
by the X-ray detectors. The CT scan requires preparatory dye to be taken by mouth 
(instruction will be given), and some will be injected shortly before the procedure itself.  
 
Risks  
PET/CT 
You will be receiving a PET/CT scan as part of your routine care so there will be no 
additional risks from taking part in this research from this procedure. Your doctor will discuss 
these risks with you. 
 
Chest x-ray, CT scan and Bone Scan 
These scans involve a small amount of radiation. Although radiation can cause cancer, the 
risk from such small doses is extremely low. The doses received from the bone scan may 
increase the risk of cancer by approximately 0.05% (5 in 1000 patients if exposed before age 
of 30), considered very low risk. CT scan and bone scan requires an injection to be given 
before the scans are done. The dye we use can cause a reaction in people who have seafood 
allergies or people who have had a previous reaction to it. This information will be asked of 
you before the procedure. 
 
Ultrasound 
Ultrasound does not use radiation and carries no radiation risk. 
You might require an extra visit to complete all the above investigation, and we will give you 
transport refund for that. This additional visit will not any planned treatment. 
 
Benefits 
There are no benefits to you from participation, but the information obtained may benefit 
others in the future. 
 
Will I be paid for participating? 
You will not be paid to participate. However, you will be provided with R50 to cover 
transport costs for an additional visit for research purposes. 
 
Are there any costs for participation?  
There are no costs for participation in the research but the visits and procedures forming part 
of your regular care will need to be paid for as usual.  
 
Do I have to be in the study?  
You have the right to refuse to participate and may withdraw whenever you like. If you 
initially decide to take part and then decide to change your mind that is okay. If you decide 
not to take part in the research, your treatment will not be affected and you will not be 
penalised in any way. 
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Who will see the information that is collected about you during the study?  
Only those involved in the study will see the information. We may want to publish the results 
in the future, but we will not use any names. 
 
What will happen to my personal information? 
Your personal information will remain confidential. 
 
Future use of data in additional research projects 
In addition to the above described research, we would like to store your clinical information 
and results from this study for research in the future, subject to approval by the Human 
Research Ethics Committee. If you give permission for storage of your data for future 
research, please indicate your acceptance on the signature page. 
 
What happens if I get hurt taking part in this study? 
While it is unlikely that you will be hurt taking part in this research, the study is covered by 
an insurance policy taken out by the University of Cape Town in case you suffer a bodily 
injury because you are taking part in the study.  
 
The insurer will pay for all reasonable medical costs required to treat your bodily injury, 
according to the SA Good Clinical Practice Guidelines 2006, which are based on the 
Association of the British Pharmaceutical Industry Guidelines. The insurer will pay without 
you having to prove that the research was responsible for your bodily injury. You may ask the 
study doctor for a copy of these guidelines. 
 
The insurer will not pay for harm if, during the study, you  
• Use medicines or other substances that are not allowed 
• Do not follow the study doctor’s instructions 
• Do not tell the study doctor that you have a bad side effect from the study procedures 
• Do not take reasonable care of yourself  
 
If you are harmed and the insurer pays for the necessary medical costs, usually you will be 
asked to accept that insurance payment as full settlement of the claim for medical costs. 
However, accepting this offer of insurance cover does not mean you give up your right to 
make a separate claim for other losses based on negligence, in a South African court.  
It is important to follow the study doctor’s instructions and to report straightaway if you have 
a side effect from the procedure. 
 
Contact details 
If you have any questions about the study, please contact Dr Paul Chilwesa (Tel. 021 404 
4286) 
If you would like to ask any questions about your rights as a research participant, please 
contact Professor Marc Blockman at the Faculty of Health Sciences Human Research Ethics 
Committee (Tel. 021 406 6338) 
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CONSENT 
 
Kindly mark box (×) if you agree to the following; 
 
• ☐I have read and understood the patient information sheet. 
• ☐I give consent to be part of this locally advanced breast cancer PET/CT vs 
Conventional imaging study 
• ☐I understand that my personal information will be anonymous when the study is 
published 
• ☐I understand that, personally, I will not benefit from this study 
• ☐I understand that I can opt out of the study at any point 
• ☐I give permission for storage of my information provided for future research 
purposes. 
 
 
 
 
______________ __ ____                     ______________________                               
__________________ 
Participant signature         Participant name   Date 
 
______________ __                            ______________________                               
__________________ 
Witness signature          Witness name    Date 
 
______________ __                            ______________________                               
__________________ 
Investigator signature       Investigator name   Date 
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1.9.4. Appendix 4: PET/CT data entry form 
 
Technical quality:   Optimal    Suboptimal  
Reason for suboptimal quality __________________________ 
 
 
AREA 1 2 3 SUV max Size CT 
characteristic 
Metastasis 
Brain        
R Breast        
L Breast        
L Axilla level 1        
L Axilla level 2        
L Axilla level 3        
L Internal mammary        
[Etc.]†        
† The datasheet continues to include the following areas: L Cervical; L Mediastinal: Level 1; L Mediastinal: Level 
2; L Mediastinal: Level 3; L Mediastinal: Level 4;L Mediastinal: Level 5; L Mediastinal: Level 6; L Mediastinal: 
Level 7; L Mediastinal: Level 8; L Mediastinal: Level 9; L Mediastinal: Level 10; R Axilla level 1; R Axilla level 
2; R Axilla level 3; R Internal mammary; R Cervical; R Mediastinal: Level 1; R Mediastinal: Level 2; R 
Mediastinal: Level 3;R Mediastinal: Level 4; R Mediastinal: Level 5; R Mediastinal: Level 6; R Mediastinal: Level 
7; R Mediastinal: Level 8; R Mediastinal: Level 9; R Mediastinal: Level 10; L Lung; R Lung; Liver; L Adrenal; 
R Adrenal; Cranium;  Mandible; L Clavicle; L scapula; L Manubrium; L Sternum; L Ribs; L Humerus; L Radius; 
L Ulna; L Pelvis; L Femur;  L Tibia; L Fibula; C Spine; T Spine; L Spine; Sacrum; R Clavicle; R scapula; R 
Manubrium; R Sternum; R Ribs; R Humerus; R Radius; R Ulna; R Pelvis; R Femur; R Tibia; R Fibula; Skin; GIT; 
GUT; Other 
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1.9.5. Appendix 5: Bone scan data entry form 
 
Technical quality:   Optimal    Suboptimal  
Reason for suboptimal quality __________________________ 
AREA 1 2 3 SUV max Size CT 
characteristic 
Metastasis 
Cranium        
Mandible        
L Clavicle        
L scapula        
L 
Manubrium 
 
       
L Sternum 
 
       
L Ribs 
 
       
[Etc.]†        
† The datasheet continues to include the following areas: L Humerus; L Radius; L Ulna; L Pelvis; L Femur; L 
Tibia; L Fibula; C Spine; T Spine; L Spine; Sacrum; L Ulna; R Clavicle; R scapula; R Manubrium; R Sternum; R 
Ribs; R Humerus; R Radius; R Ulna; R Pelvis; R Femur; R Tibia; R Fibula; Skin; GIT; GUT; Other 
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1.9.6. Appendix 6: Human ethics research committee study approval 
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2.1. Introduction 
Breast cancer is the second most common cancer in adults, second to lung cancer, and is the 
most frequent cancer diagnosed in women globally (figure 1).1 Breast cancer mortality rates are 
higher in low and middle income countries (LMIC).1,2 In South Africa, breast cancer accounts 
for more than 20% of cancers diagnosed in women (figure 2).3 Like most other African 
countries, patients are thought to present late, which accounts for the higher mortality in 
comparison to the high income countries (HICs).4 
 
 
Figure 1: Global cancer burden at a glance  
Source: WHO, 20181 
 
Breast cancer survival rate decreases to less than 60% and 20% in cases of locally advanced 
and metastatic disease, respectively.5 Staging is defined as an assessment of tumour spread in 
an untreated patient with confirmed cancer6 and is important for disease prognosis. One of the 
biggest challenges of breast cancer management in LMICs is the lack of access to new staging 
technologies, drug availability and modern radiotherapy facilities. 
 
There exists no consensus on the definition of “locally advanced breast cancer (LABC)”,7 but 
most commonly this term refers to clinical stage III disease, which is a heterogeneous group of 
advanced primary and/or nodal disease without clinically evident systemic metastases. 
Approximately 40% of patients with LABC will develop metastasis within five years post 
treatment.8,9 
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Neo-adjuvant chemotherapy (NACT) is the standard of care in LABC10 and is increasingly used 
in patients with operable breast cancer with or without axillary lymph node metastases.11,12 The 
administration of NACT must follow clinical and radiological exclusion of metastasis. The 
presence of distant metastases is the single most important prognostic factor in patients with 
breast cancer, and plays a critical role in determination of therapy.13 The importance of accurate 
staging at diagnosis of LABC is crucial to ensure that appropriate treatment is offered to 
patients, and to prevent the overtreatment of patients harbouring metastases.  
 
The three most common sites of metastasis in breast cancer are the lungs, liver and bones.14  
Historically, these subsites were targeted in the staging processes for breast cancer using 
conventional imaging (CI) of bone scintigraphy, chest plain radiography, and abdominal 
ultrasonography. Assessment of metastasis via conventional imaging (CI) should ideally 
include whole body CT and bone scans,15 however, at Groote Schuur Hospital (GSH) (Cape 
Town, South Africa) we use a chest radiograph, an ultrasound scan of the abdomen and a bone 
scan. The choice of these CI modalities at GSH is due to resource and time constraints. 
However, the sensitivity of these methods has been criticised, and previous studies have shown 
the limitations of the use of CI in the accurate staging of locally advanced breast cancer.11,13,14,16-
19  
 
The use of 18F-FDG PET/CT in cancer care is thought to provide useful clinical information 
and has been postulated to lead to significant cost savings in patient management (such as 
avoiding expensive intervention; surgery, chemotherapy, radiotherapy).20,21 Strong evidence 
has demonstrated superior diagnostic accuracy of 18F-FDG PET/CT in comparison to 
conventional imaging in staging and restaging of most cancers.22 The use of 18F-FDG PET/CT 
for disease staging of patients with locally advanced breast cancer may improve diagnostic 
sensitivity.23 However, we are still unsure of the diagnostic superiority of 18F-FDG PET/CT 
over CI specifically in LABC in the South African population. 
 
2.2. Search strategy  
A comprehensive literature search was performed by using electronic bibliographic databases 
(i.e. PubMed, MEDLINE, Scopus, Web of Science, Google Scholar, Clinical Key, Clinical 
Evidence and Cochrane Library) using the following keywords: Breast Cancer; 18F-
fluorodeoxyglucose (FDG) positron emission tomography/computed tomography; 18F-FDG 
PET/CT; Conventional Imaging; Breast cancer Staging; Locally Advanced Breast cancer; 
South Africa; Low and middle income Countries; LMICs. Studies with breast cancer and 18F-
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fluorodeoxyglucose (FDG) positron emission tomography/computed tomography were 
retrieved without restriction to language. 
 
2.3. Literature Review  
2.3.1. Breast cancer incidence and mortality  
Breast cancer is the second most common cancer in adults, second to lung cancer, and is the 
most frequent cancer diagnosed in women globally.1 Breast cancer mortality rates are higher in 
low and middle income countries (LMIC).1,2 The high cancer-related mortality rates in Africa 
are linked to multiple related factors with late presentation and diagnosis, and lack of  adequate 
treatment facilities cited as the main reasons.2,4  The mortality to incidence rate of breast cancer 
in SA is 46%.24 
 
2.3.2. Incidence and mortality in South Africa 
In South Africa, breast cancer accounts for approximately 38.5% of cancers diagnosed in 
women.3,25 Like most other African countries, patients are thought to present late, which 
accounts for the higher mortality in comparison to the high income countries(HICs).4 Globally 
breast cancer typically comprises approximately 25% of the total patient caseload.7 The 
workload of the oncology unit at Groote Schuur hospital comprise 22% breast cancer related 
work (according to the unpublished Radiation Oncology Groote Schuur hospital & University 
of Cape Town Audit of activities conducted in 2017 for the period 2013 to 2016), with the 
majority of the intake been locally advanced at presentation. The second tertiary hospital in the 
Western Cape (Tygerberg Academic Hospital) estimates the patients presenting with advanced 
breast cancer at 60% (unpublished). The breast cancer mortality rate is considered higher than 
recorded (46%) in South Africa due to unreported cases.24 This is in part due to the cancer 
registry being a pathology based registry. The age-standardized mortality rate is reported as 
15.6 per 100,000 population, and a 5-year net survival of just over 50%.24 In comparison, the 
United States averages at 90%.26 The ASR for mortality is seen to be getting worse, reported in 
2015 as 11.7 for the period spanning 2008 to 2012 to the current 15.6, which might be a 
reflection of an improvement in the reporting to the National cancer registry.26,24  
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Figure 2: South African cancer burden at a glance 
Source: WHO, 20181 
2.3.3. Importance of early detection of breast cancer 
Breast cancer survival rates decrease to less than 60% and 20% in cases of locally advanced 
breast cancer and metastatic disease, respectively.5 Staging is defined as an assessment of 
tumour spread in an untreated patient with confirmed cancer,6 and is important for disease 
prognosis. Owing to the improvement in early detection and treatment, breast cancer prognosis 
has improved globally over the last decade nearing 80% at 5 years.5 However this is not the 
case in LMICs, with the majority of cancer patients presenting at advanced or late stage.27 
2.3.4. Problem in low and middle income countries (LMICs) 
One of the biggest challenges of breast cancer management in LMICs is the lack of access to 
new and improved treatment and staging technologies, as well as that patients tend to present 
late.2,4 It is well reported that a large proportion of women with breast cancer seek medical care 
late, thereby presenting with advanced disease.4 This situation is made worse with the limited 
access to cancer treatment facilities, with most Sub-Sahara African countries lacking 
radiotherapy services, and the ones that do have face the challenges of limited access to 
affordable and quality services.26,28 
2.3.5. Locally-advanced breast cancer 
There is no consensus on the definition of “locally advanced breast cancer (LABC)”,7 but most 
commonly this term refers to clinical stage III disease, which is a heterogeneous group of 
advanced primary and/or nodal disease without clinically evident systemic metastases. 
Approximately 40% of patients with LABC will develop metastasis within five years post 
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treatment.8, 9 The presence of distant metastases is the single most important prognostic factor 
in patients with breast cancer, and plays a critical role in determination of therapy.13 
 
2.3.6. Locally advanced Breast cancer and Neo-adjuvant chemotherapy 
Neo-adjuvant chemotherapy (NACT) is the standard of care in LABC.10 This makes the surgical 
breast cancer operation (usually a mastectomy and axillary node clearance) safer and more 
successful. More recently it is also used for the conversion from a radical mastectomy to a 
breast conserving therapy. In both accounts it is only administered after exclusion of metastasis. 
Typically, NACT treatment for LABC consists of at least six cycles of combination 
chemotherapy and, according to the European Society for Medical Oncology (ESMO) and St. 
Gallen International Expert Consensus, it should include an anthracycline and a taxane 
component.29,15,30  
 
In contrast, combination chemotherapy does not provide an overall survival benefit when used 
in metastatic disease, but has a role in treatment when a rapid response is desired.15  This comes 
with a cost of increased toxicity. These drugs are highly toxic, especially when used in 
combination or sequentially when administered over 6 cycles or more. In addition there is a 
higher financial cost.  Combination chemotherapy is thus not the appropriate treatment in 
metastatic disease. 
 
Radical treatment in breast cancer refers to the use of various treatment modalities (with 
acceptable toxicities) with the aim of the complete cure of the disease. In LABC this typically 
consists of the sequential combination of multi-agent NACT, breast surgery, and radiotherapy 
with or without endocrine therapy.15 The extent of disease is important for deciding the loco-
regional treatment.  The stage of the disease is determined by the initial clinical assessment and 
radiographic findings. The diagnosis of metastatic disease immediately excludes these patients 
from radical treatment options because no curative treatment exists yet for metastatic breast 
cancer.7, 31, 32 Therefore, instead of receiving radical treatment, patients with metastatic breast 
cancer receive palliative treatment to improve quality of life. This non-curative option consists 
of targeted and/or endocrine therapy, single agent chemotherapy, and the use of radiotherapy 
for local and symptomatic control. It is therefore important that all clinically LABC patients be 
staged comprehensively before treatment is begun. 
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2.3.7. Breast cancer and common sites of metastasis 
Breast cancer is inherently heterogeneous in nature, both in intra- and inter-tumoral 
variability.33 As a consequence of this, metastatic disease varies between different molecular 
subtypes, although most commonly occur in bone, lungs and liver, in that decreasing frequency 
respectively.34 Historically, the 3 subsites namely bone, lungs, and liver were targeted in the 
staging processes for breast cancer using conventional imaging (CI) of bone scintigraphy, chest 
plain radiography, and abdominal ultrasonography. Previous studies have shown the limitations 
of the use of CI in the accurate staging of locally advanced breast cancer.11,13,14,16-19 
 
2.3.8. Bone Scintigraphy use in breast cancer 
A search of literature showed that bone is the most common site of metastases for breast 
carcinoma, accounting for on average 40% to 60% of all breast cancer metastases.7,14,17-19,35-37 
Garg et al. in a prospective study of LABC staging with FDG PET/CT compared to CI reported 
bone metastases as the most common picked up metastases, accounting for 50% and 45% on 
CI and PET/CT, respectively.17 This is in keeping with the most common molecular luminal 
subtype (approximately 85%) that is known to  metastasize to bone early in the course of the 
disease.33  
 
Osteolytic bone lesions are more common for metastatic breast cancer,38 with some authors 
reporting a few mixed lytic-sclerotic,36 however the reviewed literature does not go into the 
details of the type of bone lesions. This could limit the utility of bone scintigraphy with a 
technetium based agent, which is dependent on blood flow and osteoblastic activity: This has 
been shown to reduce the sensitivity in the more common osteolytic metastases, which has led 
to significant differences in the pick up between PET/CT and bone scintigraphy.14  
 
Bone scintigraphy still remains a reasonably good option with comparable sensitivity in 
osteoblastic and mixed lytic-sclerotic lesions to PET/CT, despite the scarcity of these type of 
lesions.14,36,39 Surprisingly, Damle et al (2013) showed a better sensitivity of 99mTc-MDP bone 
scans of 91% compared to 18F-FDG PET/CT of 73%, and Groheux et al. also showed a lower 
FDG PET/CT sensitivity in purely sclerotic bone metastases: This literature offers contradictory 
findings about the superior sensitivity of FDG PET/CT in detection of bone metastases in breast 
carcinoma, and retains the utility of 99mTc-MDP bone scintigraphy in this subset of patients.36,18 
A retrospective study conducted by Morris et al. specifically addressed this issue that has 
dominated the field of breast cancer staging.40 When he assessed if an ‘integrated positron 
emission tomography/computed tomography could render bone scintigraphy unnecessary to 
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investigate suspected metastatic breast cancer’, he found a consistency in both modalities, and 
concluded that PET/CT replacing bone scintigraphy in this setting remained unknown. 
 
2.3.9. Chest X-ray use in breast cancer 
Data on plain chest radiography, the chest X-ray (CXR), utility in the staging of LABC are very 
limited. The few available studies have shown a low yield of lung metastases, high false positive 
results, and inferior sensitivity in comparison to chest computed tomography.14,41,42 The 
problem with thoracic metastases assessment is that most patients remain asymptomatic, unless 
they are complicated by a pleural effusion.  
 
Less than a quarter of all breast cancer patients present with lung metastasis.14 Unlike bone 
metastases, thoracic metastases are said to be clinically asymptomatic and uncommon at initial 
breast cancer diagnosis. Almost 3 decades ago, Ciatto et al. argued that the use of CXR for 
thoracic assessment and staging of breast cancer was limited and inadequate with a low 
sensitivity of less than 30%.43  
 
Another consideration is that the positive findings on CXR usually requires the use of contrast-
enhanced computed tomography (CECT) for correlation and characterization due to many 
breast cancer thoracic false positives. Despite the limitations with use of CXR, Puglisi et al. in 
their prospective study on baseline staging investigations for all clinical stages of breast cancer 
showed some patients are upstaged from early breast cancer to stage IV using CI for work-up, 
stating that CXR can still be useful in ‘patients with a priori high risk of metastases’, viz-a-viz 
clinical T4 and high nodal burden.37 In most high- and middle income countries, this modality 
has been done away with in preference for CECT in the routine assessment for lung metastasis 
in LABC, which has been the preferred modality of choice for over 3 decades.15,29,44,45 
 
2.3.10. Abdominal ultrasonography uses in breast cancer 
Liver and abdominal metastases are rare in breast carcinoma at initial diagnosis.14,37 The initial 
work for liver metastases with the help of liver enzymes or imaging remains very non-specific 
and is thought to be of low diagnostic yield. The correlation of deranged liver enzymes and 
diagnostic imaging remains poor.  
 
Most recent evidence shows very similar pick-up in lung and liver metastases on both CI 
(ultrasonography abdomen, CECT) and whole body PET/CT.17-19 This can be attributed to 
advancements made in image resolution on the latest generation of ultrasonography machines 
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(the evolution of transducers has changed our ability to visualize anatomy), and an increase in 
the slice number and image reconstruction of computed tomography (CT). The preferred 
modality to investigate for symptomatic liver metastases is a contrast-enhanced computed 
tomography (CECT) or magnetic resonance imaging (MRI).15,46 The use of abdominal 
ultrasonography has been recommended as an alternative in the absence of CECT or MRI, in 
the characterization of small lesions identified on CECT.47 There is a paucity of evidence on 
the recommended use of abdominal ultrasonography (USG) in the initial staging for breast 
cancer. To date no large-scale studies have been performed to investigate the utility of 
abdominal USG in LABC. Puglisi et al (2005) thought abdominal USG still had a role in the 
staging of breast cancer with high risk for metastasis, in locally advanced disease.37 Considering 
there has also been advancement in the USG scanner and transducer capabilities since Puglisi 
et al. study, its utility in LABC requires more research and exploration.  
2.3.11. Molecular subtypes and metastases 
The limitations of the use of CI in accurately staging LABC has been further highlighted by the 
molecular classification of breast cancer which has dispelled the notion that all breast cancers 
have a well-defined pattern of metastasis: The molecular classification into the 4 distinct 
subtypes (luminal A, luminal B, HER2/neu, Basal-like), has led to breast cancer no longer being 
considered a single disease, but rather diseases characterized by different molecular 
signatures.14,33 Hormone receptor positive disease is generally thought to have a predilection 
for bone metastasis before visceral metastasis, while the triple negative and HER2/neu subtypes 
are known to send metastatic deposits early in the course of disease to lymph nodes and viscera 
respectively.14,34 Therefore, the use of CI in the staging of breast cancer creates a lot of 
opportunities for error in the restricted work-up of site and/or organ specific metastasis. 
2.3.12. Positron emission tomography/computed tomography (PET/CT) and 
breast cancer 
Positron emission tomography (PET) was introduced into clinical services in the mid-1970s for 
the purpose of brain and cardiac research. The use of PET in oncology came to the fore at the 
beginning of the 21st century, with almost 98% of all indications been staging and re-staging of 
tumours.48 PET involves the topographic assessment of biochemical processes associated with 
the process in question. The biochemical process can be a dysfunction, for example an 
inflammatory disease process, or an association of the tumour biology. The common 
radiopharmaceutical used, 18Fluorine-Fluorodeoxyglucose (18F-FDG), takes advantage of the 
differential utilization of glucose at the cellular level between normal tissue and malignant 
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tumour cells. Tumours have been shown to have a higher tumour cell uptake of 18F-FDG 
secondary to increased tumour cells glycolysis.49 18F-FDG PET/CT measures the accumulation 
of the radiopharmaceutical (18F-FDG) in tumour cells picked up on PET and co-registered with 
the CT component for anatomical localization, a hybrid technology. 
 
Given the problems and limitations of site specific staging investigations (conventional 
imaging) in breast cancer, PET was considered and introduced as a suitable alternative.  One of 
the first studies aimed at comparing the use of PET with CI in breast cancer, showed the benefit 
of PET in the upstaging of patients and it had superior accuracy in the detection of distant 
metastasis, thus influencing a change of management of patients. The Schirrmeister et al. study 
of 18F-FDG PET in pre-operative staging of breast cancer in comparison with standard 
procedures (conventional imaging) made a conclusion that PET was better at the detection of 
distant metastasis, with the presence mediastinal and thoracic metastases being the highest.16 
The limitations of this study was that it was retrospective, comprised a heterogenous breast 
cancer histologies, and only 10% of all patients had clinically advanced (stage III) disease. They 
did not, however, recommend the use of PET in staging of breast cancer at initial presentation 
due to the low incidence of metastases at initial presentation, and due to its limited availability. 
Their findings were also confirmed by Dose et al. who found and concluded that FDG PET was 
superior in the detection of pulmonary metastases, and more so of mediastinal lymph node 
metastases in comparison to CXR, while the its sensitivity for liver and bones was similar to 
abdominal USG and bone scintigraphy respectively.13 The recommendation was then made for 
FDG PET in locally advanced disease, i.e. clinical high tumour stage or axillary node positive 
disease. 
 
The clinical stage of breast cancer at which the use of 18F-FDG PET/CT could be performed 
with a good balance of cost and clinical superiority to CI remained unclear for almost a decade 
since its introduction in oncology. Reviewed literature has shown 18F-FDG PET/CT  utility to 
be maximal after clinical stage IIB, with the American (NCCN- National Comprehensive 
Cancer Network) and French (NCI- National Cancer Institute) making protocol adjustment of 
recommending 18F-FDG PET/CT use in identification of unsuspected regional lymph nodal 
disease or distant metastases in LABC when used in addition to standard imaging studies (CI) 
and as a single procedure as an option in LABC, respectively.32,50,51,52  
 
The use of 18F-FDG PET/CT for staging in a selected group of high-risk breast cancer patients 
has been shown to be accurate in identifying metastases.18,49 Groheux et al. found 18F-FDG 
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PET/CT to be more superior to CI, stating that the maximal utility of 18F-FDG PET/CT in breast 
cancer lies in the staging of locally advanced and inflammatory breast cancer, with an advantage 
over CI of allowing the examination of extra-axillary nodes as well as chest, abdomen, and 
bone in a single session.18 This study also highlighted the importance of breast cancer 
histological and molecular subtype stratification for 18F-FDG PET/CT indications, as they 
found variability in 18F-FDG uptake, and recommended its use in locally advanced non- lobular 
breast cancers.  
 
Similar studies conducted in India, comparing 18F-FDG PET/CT and CI, designed in settings 
similar to ours are in agreement with the findings by Groheux et al.18 Garg et al. prospectively 
found that 18F-FDG PET/CT detected ipsilateral supraclavicular and internal mammary nodes, 
thereby upstaging patients, and outperformed all CI modalities in the detection of distant 
metastases.  The shortfall of this study was the lack of histopathologic confirmation of 
metastatic lesions. They recommended the addition of CT to CI, hypothesizing that its addition 
was likely to improve sensitivity of CI and lead to more accurate staging. A prospective study 
by Gajjala et al.18 conducted in India, designed in accordance with the recommendations of 
Garg et al. and with the addition of CECT to CI, found 18F-FDG PET/CT to be more accurate 
than CI for staging and modification of stage and treatment of LABC.19 CECT of the chest was 
however, more superior over 18F-FDG PET/CT for the detection of pulmonary metastasis. The 
18F-FDG PET/CT had more false positives in the lung in comparison to CECT, with one case 
reported to be a lung abscess on biopsy. In agreement with previous studies, 18F-FDG PET/CT 
outperformed CI despite the addition of CECT. 
 
When used appropriately in oncology, 18F-FDG PET/CT has been shown to provide useful 
clinical information and has been postulated to lead to significant cost savings in patient 
management (such as avoiding expensive intervention; surgery, chemotherapy, 
radiotherapy).20,21 Strong evidence has demonstrated superior diagnostic accuracy of 18F-FDG 
PET/CT in comparison to conventional imaging in staging of locally advanced breast cancers. 
The use of 18F-FDG PET/CT for disease staging of patients with locally advanced breast cancer 
may improve diagnostic sensitivity.23 
 
The use of 18F-FDG PET/CT in breast cancer needs to be done cautiously. Breast cancer is a 
heterogenous disease, with proven variable radiopharmaceutical uptakes. Tagliabue et al. gives 
an important caution on the use of 18F FDG PET/CT in breast cancer stating the requirement 
for the knowledge of its potentials and limitations as some of the findings may be misleading.48 
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The uptake of 18F-FDG by lymph nodes should always be confirmed due to the known low 
specificity of this radiopharmaceutical.53 Despite Schirrmeister et al. study been retrospective, 
they found as high as 20% false-negative rate for detection of lymph node metastases in breast 
cancer when using 18F-FDG PET, but this was a heterogeneous group of participants that 
included early breast cancer, and also included invasive lobular carcinoma which often cannot 
be accurately staged by 18F-FDG PET.16 Furthermore, research suggests that the merit of this 
technology for screening and work-up is questionable because no large prospective studies have 
been done and due to the high rate of false negative sclerotic bone lesions on 18F-FDG PET.22 
However PET does have superior detection rates once combined with CT. In addition, although 
some studies have compared whole-body PET/CT with conventional imaging, most of the 
results have been criticised: The limitation of many of these studies is they were retrospective, 
and without histologic confirmation of suspected metastases.8,5,18 Very few prospective studies 
have been conducted in the developed world, and those that have, have been limited by their 
bias for breast cancer recurrence or metastatic disease and lack of histopathological 
stratification.11,54,55,56 
 
The use of 18F-FDG PET/CT in breast cancer remains a controversial argument, with two 
commonly referenced professional communities, NCCN and ESMO, not categorically 
recommended its use in the upfront staging procedures. NCCN in the last 2 clinical versions 
recommend the use of 18F-FDG PET/CT in breast cancer staging in circumstances where 
conventional imaging remains suspicious or is equivocal in locally advanced disease,32,46 FDG 
PET/CT is most useful in situations where standard imaging results equivocal or suspicious’ 
because a few studies support its potential role for this indication.  The panel further recommend 
consideration for biopsy of these equivocal or suspicious sites for accurate staging.  
 
In 2013 ESMO recommended that, if PET/CT is available, it may be used (instead of and not 
on top of standard staging procedures) in LABC staging, but this was a weak recommendation 
(IIB).29  The 2018 ESMO recommendation on the staging of LABC is non-committal, ‘minimal 
staging work-up for ABC (advanced breast cancer) includes a history and physical examination, 
haematology and biochemistry tests, and imaging of chest, abdomen and bone’, it is without a 
clear direction of what imaging technique(s) are to be employed. ABC is a heterogenous group 
comprising locally advanced and metastatic breast cancers.15  
 
The use of PET/CT services in South Africa was introduced in 2007. A caution by the College 
of Nuclear Physicians (CNP) of South Africa was given, due to the high TB prevalence in the 
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South African population care needs to be taken over FDG-avid lesions, with such lesions 
creating a risk of a considerable number of false positive scans.57  The extrapolation of evidence 
gathered from developed Countries on PET/CT was not recommended by the CNP at the time 
of it been introduced in South Africa, stating that diagnostic accuracy depends in part to 
prevalence of disease in the population, and such data might not be as accurate for the majority 
of the South African population. In consonance with NCCN recommendations, the CNP stance 
on the PET/CT indications for LABC is in select cases as an adjunct to conventional imaging 
when CI modalities used are said to be equivocal.58 
Accurate detection of metastases can reduce the number of radical treatments and alter course 
of disease. On the other hand, failure to detect metastases can lead to poor quality of life. The 
initial 18F-FDG PET/CT recommendation in breast cancer staging was for multifocal disease or 
suspected disease recurrence.59 It is clear that more evidence, preferably level I, on the 
indications of 18F-FDG PET/CT in breast cancer staging is warranted. 
2.4. Conclusion 
Based on information and evidence presented above, the importance of accurate staging at 
diagnosis of LABC is clear and crucial to ensure appropriate treatment is offered to patients, 
and for prevention of unnecessary overtreatment of patients harbouring metastases. Assessment 
of metastases via conventional imaging (CI) ideally include whole body CT and bone scans.15 
However, at Groote Schuur Hospital we used a chest radiograph, an ultrasound scan of the 
abdomen and a bone scan (targeting the three common areas for breast metastasis). The choice 
of CI at GSH was due to resource and time constraints for the use of whole body CT scan 
against the high volume of patients in the breast cancer clinic.   
In May 2015, PET/CT became available for use in the combined breast MDT.  Based on the 
available evidence given above from the NCCN,44,60 CNP, and ESMO,29 and clinical experience 
by the local GSH breast cancer MDT, 18F-FDG PET/CT was introduced for the staging of 
invasive ductal carcinoma (IDC) LABC in HIV negative patients at Groote Schuur Hospital 
(GSH).  
Evidence has pointed out that, there is considerable biologic variability within breast cancer,33,61 
which results from factors that influence the development of the disease. These factors include, 
but are not limited to, environmental causes, genetic factors and race.62 PET/CT is a hybrid 
investigation that focuses on biological and anatomical localization of disease, thus breast 
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cancer biology differences might have a role to play.18 Results from other studies cannot always 
be extrapolated to our settings without a consideration for the differences in the causal factors 
between various geographical regions. To the best of our knowledge there is no existing 
prospective data comparing the use of 18F-FDG PET/CT with conventional imaging in IDC 
LABC in the South African or African population.  Therefore, the focus of this research project 
is to develop an understanding of the diagnostic accuracy and superiority of 18F-FDG PET/CT, 
in comparison to conventional imaging modalities, in the staging of locally advanced breast 
cancer. The outcomes of this research will provide evidence that may inform the local clinicians 
on the appropriate use of 18F-FDG PET/CT in locally advanced breast cancer in South Africa.  
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1.2. Abstract  
 
Background: Breast cancer is the second most common cancer in adults and the most frequent 
cancer diagnosed in women. In South Africa, breast cancer accounts for 38.5% of cancers 
diagnosed in women. Since the presence, extent and location of distant metastases is one 
important prognostic factor in locally advanced breast cancer (LABC), accurate staging at 
diagnosis is crucial to ensure patients receive the appropriate treatment. Increasing evidence 
shows that the use of 18F-FDG PET/CT for disease staging of LABC may improve diagnostic 
sensitivity.  
Aim: To prospectively assess the difference in diagnostic accuracy between whole-body 
PET/PET-CT and conventional imagine (CI) for staging LABC.  
Methods: A total of 42 participants with clinical stage III and a select few stage II breast cancer 
underwent both 18F-FDG PET/CT and CI.  
Results: 18F-FDG PET/CT found significantly more (p=0.0077) distant metastatic sites than CI 
(36% vs. 21%). 18F-FDG PET/CT upstaged 9 (21.4%) of patients from clinical stage IIIa to 
stage IIIc, and changed in management of 54 % of patients. Thirsty-eight percent (38%) of the 
patients had their clinical stage unchanged. One of 5 suspected metastatic sites 18F FDG 
PET/CT on biopsy was positive for malignancy. 
Conclusion: The 18F-FDG PET/CT is useful for staging locally advanced non-inflammatory 
infiltrating ductal carcinoma of the breast. Use of 18F-FDG PET/CT was superior to 
conventional imaging in assessing metastatic mediastinal lymphadenopathy, but with a poor 
specificity. The use of 18F-FDG PET/CT in LABC is useful, with the biopsy of isolated 
suspicious lesions for metastasis increasing its accuracy. (Words: 247) 
 
1.3. Keywords 
Locally advanced breast cancer; NACT; 18F-FDG PET/CT; Conventional imaging; Staging; 
South Africa; LMICs 
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1.4. Introduction 
Breast cancer is the second most common cancer in adults, second to lung cancer, and is the 
most frequently diagnosed cancer in women globally.1 In South Africa, breast cancer is the 
commonest type of cancer affecting women and accounts for 26% of all female cancers, 
excluding non-melanoma skin cancers.2 Like most other African countries, many patients 
present late with locally advanced disease (clinical stage III),3-5 which may account for the 
higher mortality in comparison to the high income countries(HICs).6 
Approximately 40% of patients with locally advanced breast cancer (LABC) will develop 
metastasis within five years after treatment.7, 8 The presence or absence of distant metastases is 
the single most important prognostic factor in these patients, and plays a critical role in 
determination of appropriate therapy.9 Correctly staging this group of patients is therefore 
crucial in the disease management and prognostic planning.  
At Groote Schuur Hospital in the Western Cape, patients diagnosed with LABC were 
previously staged with conventional imaging (CI) consisting of a chest x-ray, abdominal 
ultrasonography, and bone scintigraphy. This has since changed to the use of contrast-enhanced 
computed tomography (CECT) of chest and abdomen, and bone scintigraphy. A clinical 
argument exists concerning the need to use more sophisticated technology in the accurate 
staging of women with LABC in order to correctly exclude patients with metastatic disease 
from aggressive therapies.10 Existing evidence has demonstrated superior diagnostic accuracy 
of 18F-FDG PET-CT in comparison to CI in staging and restaging of most cancers.3, 11-14 The 
use of 18F-FDG PET/CT for disease staging of patients with LABC may improve diagnostic 
sensitivity. 
Most studies assessing the clinical utility of 18F-FDG PET/CT for LABC staging have emerged 
from high income countries.9, 12, 15-18 A limited number of studies conducted in LMICs 
comparing 18F-FDG PET/CT with CI have shown superior accuracy of 18F-FDG PET/CT in the 
detection of distant metastasis in LABC.3, 14 Two international guidelines, the National 
Comprehensive Cancer Network (NCCN) from North America and European Society for 
Medical Oncology (ESMO), agree regarding the clinical utility of 18F-FDG PET/CT in breast 
cancer, and recommend its use when conventional imaging modalities are equivocal or 
suspicious in locally advanced inoperable, non-inflammatory breast cancer.19-21 However, there 
remains some uncertainty regarding the diagnostic superiority of 18F-FDG PET/CT compared 
to CI in LABC in South Africa. 
The use of PET/CT services in South Africa was introduced in 2007. The College of Nuclear 
Physicians (CNP) of South Africa cautioned that  due to the high TB prevalence in the South 
African population, and endemic prevalence in the Western Cape specifically, care needed to 
be taken over interpretation of FDG-avid lesions, due to the risk of false positive lesions.22 The 
extrapolation of evidence from developed Countries on PET/CT was not recommended by the 
CNP at the time, stating that diagnostic accuracy depends in part on the prevalence of disease 
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in the population, and such data might not be accurate for South Africa.20 Findings from the 
local context would be important to provide evidence of the clinical utility of 18F-FDG PET/CT 
in LABC, and dispel the concern of over-reporting of metastasis in high TB prevalence areas. 
The aim of this study was to assess the difference in diagnostic accuracy between whole-body 
18F-FDG PET/CT and CI for staging of LABC in our local geographical setting. 
 
1.5. Materials and methods 
1.5.1. Study design 
This prospective single-blinded study involved female patients presenting with locally 
advanced breast cancer (LABC) at the breast cancer outpatient clinic at Groote Schuur Hospital 
(GSH), Cape Town South Africa between January 2017 and December 2017.   
 
1.5.2. Study setting 
Groote Schuur Hospital (GSH) is a large tertiary-level state and academic hospital. It is one of 
two tertiary hospitals providing oncology care to the population of the Western Cape province. 
 
Staging for LABC at GSH has typically relied on a chest radiograph, an ultrasound scan of the 
abdomen and whole-body bone scintigraphy (targeting the 3 common sites for breast 
metastasis). Early clinical stage breast cancer (T1N0, T2N0) does not routinely have radiologic 
staging investigations, except a plain chest radiograph. The intermediate group of patients 
(T1N1, T2N1T3N0) undergo a plain chest radiograph and abdomen-pelvis ultrasonography, or a 
CECT of the chest and abdomen as well as a whole-body bone scintigraphy if symptomatic 
and/or if elevated alkaline phosphatase is noted. The rest of the LABC (T3, N1+T4, N0+) cohort 
undergo a CECT of chest and abdomen, and a whole-body bone scintigraphy.  
 
During the study period, all IDC LABC patients were staged with 18F-FDG PET/CT and 
managed radically or palliatively accordingly. All patients were discussed in an MDT, and 
appropriate decisions were made depending on 18F-FDG PET/CT findings and/or subsequent 
biopsy results.  
 
1.5.3. Study sample 
All consecutive female patients presenting with LABC at GSH during the relevant period were 
offered enrolment into the study, with the target of recruiting a total of 48 participants. 
Participants were eligible for participation if they were over 30 years of age, able to undergo 
radical treatment, and if they had newly diagnosed IDC stage III or LABC found to be 
irresectable upfront, good performance status (ECOG 0-2), and no co-morbidities that would 
restrict use of 18F-FDG PET/CT, and infiltrating ductal carcinoma (IDC) on histology. 
 
Patients who had previous malignancies, and patients younger than 30 years were excluded 
because of the higher risk for radiation-induced malignancies. Patients who had known 
HIV/AIDS and/or tuberculosis were excluded, as were patients with early breast cancer (stage 
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I or II), those who were pregnant or lactating, male patients, patients with breast cancer 
recurrence, and those who did not give consent. 
 
Sample size was estimated based on previous similarly designed studies, with an expected 40% 
difference in detection of metastasis between use of 18F-FDG PET/CT and CI for clinical T3/T4 
disease, irrespective of nodal status. We used an alpha value of 0.05 and a power of 80% to 
estimate a required sample size of 38 participants.23, 24 An extra 10 participants were recruited 
to account for the possibilities of failure to complete investigations, ineligibilities, and consent 
withdrawals.   
 
1.5.4. Procedures 
Patients meeting eligibility criteria were identified during routine examination at the breast 
cancer clinic of the surgical out-patient department (SOPD) at GSH. Suspected LABC patients 
were assessed with the help of a surgical consultant. All participants underwent routine clinical 
examination, fine needle aspiration cytology (FNAC) and a core biopsy of the tumour for 
histological confirmation and type, as well as immunohistochemistry (IHC) for hormone 
receptor status, and HER2/neu amplification status as per GSH breast cancer protocol 
guidelines. The Ki67 and Bright-Field HER2 Dual In-Situ Hybridization (B-DISH) test, 
performed for equivocal IHC HER2/neu amplification (scored at 2) were only requested if the 
MDT deemed them important for the management of the patient. This was because almost all 
LABC, irrespective of Ki67, would receive the same NACT combination regimen, and because 
anti-HER2/neu therapy (trastuzumab) was not available on protocol due to cost constraints. The 
conventional investigations included serum haematology and chemistry, breast mammogram 
and ultra-sonography, chest radiographs, abdominal-pelvic ultrasonography, and 99mTc-MDP 
bone scan. Patients with known HIV and diabetes were excluded. 
 
18F-FDG PET/CT scans were performed on a GEMINI TF Big Bore PHILIPS whole-body 
scanner. Participants were prepared, injected and imaged in accordance with the FDG PET/CT: 
EANM procedure guidelines for tumour imaging: version 2.0 (2015).25 Images were interpreted 
by two  nuclear medicine physicians and a radiologist who were blinded to all imaging results. 
All sites of abnormal 18F-FDG uptake (areas that did not conforming to normal physiological 
uptake) were recorded. For all sites, Maximum Standard Uptake Value (SUVmax), size and CT 
characteristics were recorded. If the SUVmax within the lesion was greater than that of the liver 
and CT finding were characteristic for metastasis, the lesion was scored as 3. If either the 
SUVmax or CT findings were characteristic for metastasis, the lesion was scored as 2. If neither 
the SUVmax or CT findings were characteristic the lesion was scored as 1. Thus, each site was 
scored by consensus as 1=negative for metastasis; 2 =equivocal for metastasis; 3=consistent 
with metastasis. Disagreements in scores were resolved through consultation with a third 
Nuclear Physician and a second Radiologist who then made the final decision. If there was no 
consensus among the 2 nuclear physicians and the diagnostic radiologist, a third nuclear 
physician opinion was sought. 
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The conventional investigations were performed as follows: 
• 99mTc MDP Bone scans were performed on a Siemens eCam Signature 2006 dual 
head gamma cameras. SPECT/CTs, when required were performed on a Symbia 
TruePoint 2012 SPECT/CT camera. All patients were prepared, injected, and 
imaged in accordance with the EANM practice guidelines for bone scintigraphy.26 
Images were viewed using HERMES Gold version 4.15.  
• Liver and abdominal ultrasound using a Toshiba TUS X100 2017 model, using a 6 
MHZ frequency probe. 
• Plain chest radiographies using a General Electric (GE) 6000 X-ray machine, 2008 
model. 
 
Conventional imaging and 18F-FDG PET/CT were performed within a three-week period of 
each other to avoid treatment delays and minimise reported differences in disease stage. 
Regardless of imaging protocol used, patients thought to have isolated metastases in distant 
lymph nodes or organs beyond the drainage area of the breast were subjected to biopsy for 
cytologic or histologic confirmation. When biopsy of the isolated lesions was deemed by the 
MDT to be too risky for the patient, the patient was treated as non-metastatic, and a planned 
follow-up scan was requested. Isolated lung lesions were biopsied via CECT-guided biopsy or 
endobronchial ultrasound (EBUS)-guided with trans-bronchial needle aspiration (TBNA), 
depending on which modality was deemed safer. The EBUS-TBNA was used to cytologically 
confirm the presence of IDC breast cancer in intrathoracic nodes that showed increased activity 
on 18F-FDG PET scanning. These lesions were identified following a combined reading of the 
CT and PET scan by both radiologists and nuclear medicine physicians. In conjunction with the 
pulmonologist a directed biopsy procedure was planned. After the staging investigations, 
patients were discussed in an MDT and treated as per departmental guidelines, based on 18F-
FDG PET/CT findings.  
 
1.5.5. Data collection 
Relevant demographic information was extracted from participants’ clinical folders. 
Information included: comorbidities, clinical stage (2010 AJCC TNM staging system, 7th 
edition), histopathologic subtype, immunohistochemistry markers (ER/PR and HER2 status), 
B-DISH results in patients found to have equivocal HER2 results on IHC, Ki-67 in patients 
with luminal disease if this had an impact on treatment decision making, mammogram 
(BIRADS score 1-6, presence of lymph nodes), Breast ultrasound scan (if done), CXR, bone 
scintigraphy, abdominal ultrasound, 18F-FDG PET/CT, liver functions and full-blood count 
results. All sites of abnormal 18F FDG uptake (areas not conforming to normal physiological 
18F-FDG uptake) and areas of 99mTc-MDP bone scan abnormalities were documented in a 
specifically designed standard case report form for each participant. The CXR and USG were 
generated from the radiologist reports. Each area had a designate score (1 = negative for 
metastasis, 2 = equivocal for metastasis, 3 = consistent with metastasis). 
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1.5.6. Data analysis 
Statistical analysis was done using Stata version 15.1 (StataCorp. 2017.). Continuous variables 
were summarized as mean and standard deviation while nominal and ordinal variables were 
summarized as counts and percentages. The McNemar test for matched pairs was used to 
evaluate whether there was a difference between proportions of positive 18F-FDG PET/CT and 
CI findings. A p-value of <0.05 was used to assess statistical significance. 
1.6. Ethical considerations 
The study was approved by the Human Research Ethics Committee of the University of Cape 
Town (HREC REF: 900/2016). All participants provided written consent. Data was 
anonymized using a study number to code for each folder number and stored in a Microsoft 
(MS) Excel spreadsheet on a password protected computer.  
1.7. Results 
Forty-eight participants were recruited; however, 6 were excluded; 2 because of poor quality 
18F-FDG PET/CT scans, 1 because of metaplastic histology, and 3 because they did not 
complete the investigations for analysis. The final analysed sample consisted of 42 participants. 
The clinical and demographic characteristics of patients with newly diagnosed LABC are 
summarised in Table 1. The mean (±SD) age of the participants was 51.5 (±12.71) years, 
(Range: 27 to 77 years).  Slightly more patients were post-menopausal (52.4%) than pre-
menopausal (47.6%), based on a history of one year of uninterrupted absence of menstruation.  
More patients had cancer in the right breast (57.1%) than the left. The patients were 
predominantly of luminal type disease (66.7%). The stage at presentation was mainly stage IIIB 
(54.8), with the majority (52.38%), having clinical T4b disease (skin ulceration, peau d’orange 
or satellite nodules; or palpable nodal disease (90.48%).  
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Table 1. Demographic and clinical characteristics of participants (N=42). 
Variables n (%) 
Menopausal status 
Pre-menopausal 20 (47.6) 
Post-menopausal 22 (52.4) 
Smoking history, pack years 
Nil 28 (66.7) 
<10 5 (11.9) 
≥10 9 (21.4) 
Sidedness of the breast cancer 
Right 24 (57.1) 
Left 18 (42.9) 
Clinical Stage (AJCC/TNM 7th Ed) 
Stage IIB 1 (2.4) 
Stage IIIA 12 (28.6) 
Stage IIIB 23 (54.8) 
Stage IIIC 6 (14.3) 
Histology 
Invasive ductal cell carcinoma 42 (100) 
Molecular subtype 
Luminal 11 (26.2) 
Luminal HER2 overexpressed 5 (11.9) 
Luminal HER2 equivocal 12 (28.6) 
HER2/neu over-expressed 3 (7.1) 
TNBC 11 (26.2) 
AJCC, American Joint Committee on Cancer; TNM, tumour, node, 
metastasis; HER2, human epithelial growth factor receptor 2 based on IHC; 
TNBC, triple negative breast cancer 
 
18F-FDG PET/CT upstaged 9 (21.4%) of patients from clinical stage IIIa to stage IIIc (Table 2), 
and changed management decision in 54% of the patients. Three of the 9 patients had a biopsy 
of the nodes, with 2 having results negative for cancer cells resulting in their down-staging. 18F-
FDG PET/CT (n=17, 40.5%) detected significantly more (p=0.0077) distant metastasis than CI 
(n=9; 21.4%; Table 3). 
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Table 2. Detection of metastasis by 18F-FDG PET/CT compared to CI in 42 patients 
Case Clinical 
stage 
18F-FDG PET/CT CI Biopsy Stage after 18F-FDG PET/CT Stage after biopsy Management change 
1 T2N1 Negative Negative Not applicable T2N1 Not applicable No 
2 T4bN1 Negative Negative Not applicable T4N3 (IMN) Not applicable Upstaged 
3 T4bN2 Positive Positive Not done (multiple areas) T4N3M1 Not applicable Yes 
4 T4bN2 Positive Negative Not done (too risky, close to vessels) T4N2M1(lung) Not applicable Yes 
5 T4bN1 Positive Negative Not done, declined T4N3M1(mediastinal node)  Not applicable Yes 
6 T4bN1 Negative Negative Not applicable T4N1 Not applicable No 
7 T4bN2 Negative Negative Not applicable T4N3(IMN) Not applicable Upstaged 
8 T4aN0 Negative Negative Not applicable T4N0 Not applicable No 
9 T4bN1 Negative Negative Not applicable T4N1 Not applicable No 
10 T4bN3 Positive Positive Not done (multiple areas) T4N3M1 Not applicable Yes 
11 T4bN1 Positive Negative Station 2 node T4N1M1 T4N1M0 No, biopsy negative 
12 T3N1 Positive Positive Not done (multiple areas) T4N3M1 Not applicable Yes 
13 T4bN0 Negative Negative Not applicable T4N1 Not applicable Upstaged 
14 T4bN2 Negative Negative Not applicable T4N2 Not applicable No 
15 T4bN1 Negative Negative Not applicable T4N1 Not applicable No 
16 T4aN1 Negative Negative Not applicable T4aN1 Not applicable No 
17 T3N1 Negative Negative Supraclavicular node T3N3 T3N1 No 
18 T4bN3 Positive Negative Not done, declined T4N2M1(lung) Not applicable Upstaged 
19 T2N2 Negative Negative Not applicable T2N3(IMN) Not applicable Upstaged 
20 T3N1 Positive Negative Thyroid T3N0, second primary T3N0 No 
21 T3N2 Positive Positive Not done, multiple areas T3N3M1(multiple) Not applicable Yes 
22 T3N1 Positive Negative Too risky T3N1M1(PALN) Not applicable Yes 
23 T4bN2 Positive Positive Not done (bilateral lung) T4N2M1 Not applicable Yes 
24 T3N1 Negative Negative Not applicable T3N1 Not applicable No 
25 T3N1 Negative Negative Not applicable T3N0 Not applicable Down-staged 
26 T4cN3 Positive Positive Not done (multiple) T4N3M1 Not applicable Yes 
27 T3N1 Negative Negative Not applicable T3N1 Not applicable No 
28 T4bN2 Negative Negative Not applicable T4N3M0 Not applicable Upstaged 
29 T4bN3 Positive Positive Not done (multiple) T4N3M1 Not applicable Yes 
30 T4bN0 Negative Negative Axilla T4N1 T4N0 No 
31 T2N2 Positive Positive Not done (multiple) T2N3M1 Not applicable Yes 
32 T4aN1 Negative Negative Not applicable T4N3(IMN) Not applicable Upstaged 
33 T3N3 Negative Negative Supraclavicular node T3N3 T3N3 Yes 
34 T3N1 Negative Negative Not applicable T3N1 Not applicable No 
35 T4bN1 Negative Negative Not applicable T4N3(IMN) Not applicable Upstaged 
36 T3N2 Positive Negative Lung T3N0M1 T3N0M0 Down-staged 
37 T4bN2 Negative Negative Not applicable T4N2 Not applicable No 
38 T2N3 Negative Negative Not done (Rx started before biopsy of node) T2N3 Not applicable No 
39 T3N2 Negative Negative Not applicable T3N3 Not applicable Upstaged 
40 T4bN1 Positive Positive Not done (multiple areas) T4N3M1 Not applicable Yes 
41 T4bN2 Positive Negative MDT decision not to biopsy T4N2M1(station 2)  Not applicable Yes 
42 T4bN0 Positive Negative Not done, spine T4N1M1 Not applicable Yes 
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Table 3. 18F-FDG PET/CT versus CI cross-tabulation 
Conventional 
imaging 
18F-FDG PET/CT 
Regional uptake 
(Negative), n 
 Metastatic 
(positive), n 
Total, n 
Negative, n 25  8 33 
Positive, n 0  9 9 
Total, n 25  17 42 
 
Chest X-ray showed evidence of lung metastasis in 8 patients, ultrasonography of the abdomen 
detected liver metastasis in 5 patients, while bone scintigraphy showed skeletal metastasis in 5 
patients (Table 4). The majority of detected metastases on 18F-FDG PET/CT were in 
mediastinal lymph nodes (26%).  
 
Table 4. Metastatic sites*on CI and 18F-FDG PET/CT 
Metastatic 
Site 
CI, n 18F-FDG 
PET/CT, n 
Total 
 Bone Scan CXR USG   
Bone 5 - - 7 7 
Lungs - 8 - 8 8 
Liver - - 5 4 5 
Distant LN - - - 12 12 
Brain    0 0 
Abbreviations: LN, lymph node; CXR, chest X-ray; USG, ultrasonography 
*Certain patients had metastasis in multiple sites. 
 
18F-FDG PET/CT detected axillary uptake in 37 (88%) patients while clinical examination 
detected axillary lymphadenopathy in 38 (90%) patients. Of the 4 patients without clinical nodal 
disease, 3 had FDG-avid nodes. Of the 5 patients without significant 18FDG PET/CT uptake, 4 
had clinical N1 disease and 1 had clinical N2 disease. The negative 18F-FDG PET/CT in a 
patient with clinical N2 disease had an isolated left lung nodule seen on 18F-FDG PET/CT.  
 
18F-FDG PET/CT detected ipsilateral supraclavicular lymphadenopathy in 10 (23.8%) patients, 
which was clinically detected in only 5 (11.9%) patients (Table 2). 18F-FDG PET/CT detected 
internal mammary lymphadenopathy (IMN) in 11 (26.1%) patients, 4 (9.5%) of whom had 
bilateral IMN. Overall, N3 disease, which was not recognized by either clinical examination or 
conventional imaging, was identified on 18F-FDG PET/CT in an additional 11 (26.1%) patients. 
Three of the patients with supraclavicular nodal disease detected on 18F-FDG PET/CT were 
subjected to a biopsy by MDT recommendation, and 2 of these were found to be negative on 
histopathology and/or cytology (Figure 1). All the N3 disease detected on 18F-FDG PET/CT 
was clinically at least T4b and/or N2 or N3 (Table 2). 
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Comparison of 99mTc-MDP bone scan with 18F-FDG PET/CT (Table 4): The bone scan detected 
bone metastasis in 5 (12%) patients, with the common sites being thoracic and lumbar vertebrae. 
The bone scan missed 2 osteolytic osseous metastatic lesions in the thoracic and lumbar 
vertebrae that were detected on 18F-FDG PET/CT. All the lesions detected on bone scan were 
also detected on 18F-FDG PET/CT. However, the 18F-FDG PET/CT detected more bone 
metastatic sites than the bone scan in all patients with bone metastases, with one patient having 
12 different bone sites detected on 18F-FDG PET/CT compared to 7 on bone scan. All the 
patients in this study but one had abnormal haematological blood results, with correlation found 
between an abnormal blood results and metastatic bone disease. 
 
Comparison of chest X-ray with 18F-FDG PET/CT (Table 4): Pulmonary metastasis was 
detected in 8 patients (19%) on plain chest X-ray, which was equal to the number detected on 
18F-FDG PET/CT, but 2 were not in the same patients nor in the same anatomical locations. 
The 2 patients with suspected lung metastasis on chest X-ray were not detected on the 18F-FDG 
PET/CT. The patient with an isolated lung metastasis detected on 18F-FDG PET/CT was 
subjected to an endobronchial ultrasound (EBUS) guided biopsy. This lesion was not detected 
on chest X-ray. The result of the EBUS guided biopsy was negative.  
 
Comparison of abdominal ultrasonography with 18F-FDG PET/CT (Table 4): The abdominal 
ultrasound detected 5 suspicious metastatic liver lesions, with 18F-FDG PET/CT picking up 4. 
The one patient with a suspected liver lesion picked up on abdominal ultrasound, and not 
detected on 18F-FDG PET/CT, was too small to characterize or to biopsy. The 18F-FDG PET/CT 
liver findings correlated well with abnormal liver function tests. 
 
18F-FDG PET/CT detected 11 distant lymph nodes (Table 4): The majority (9/11) of distant 
metastatic lymph nodes were mediastinal. The isolated para-aortic lymph node detected on 18F-
FDG PET/CT was not biopsied as the MDT considered the procedure too risky for the benefit 
and elected to treat the patient as having metastases, and to repeat the 18F-FDG PET/CT at 
completion of the Neo-adjuvant chemotherapy (NACT). 
 
Patients with isolated metastases detected on 18F-FDG PET/CT were supposed to be subjected 
to biopsy according to protocol. An isolated station 2 mediastinal lymph node was subjected to 
an endobronchial ultrasound (EBUS) guided biopsy and was found to be negative on cytology 
and cell-block (Figure 2). The isolated lung metastasis detected on 18F-FDG PET/CT was 
subjected to a CT-guided biopsy (Figure 3), in a 43-year-old luminal non-HER2 disease patient. 
The radiologist performing the biopsy was availed the PET/CT images prior to the CT-guided 
biopsy procedure. The histopathology results were negative for metastatic or infectious 
diseases. 
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Figure 1: A 32-year-old with TNBC with suspicious right supraclavicular node on FDG 
PET/CT. SUVmax Primary disease 24.7, Supraclavicular node 3.5. Biopsy results were 
negative for malignancy.  
Figure 2: A 55-year-old with luminal disease with a station 2 mediastinal lymph node 
suspicious for metastasis on FDG PET/CT. Subjected to endobronchial ultrasound guided 
biopsy. SUVmax breast primary 8.4 node 3.4. Biopsy results were negative for malignancy. 
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Figure 3: A 43-year-old with luminal disease with a left lung non-spiculated lesion 
suspicious on FDG PET/CT. Subjected to a CT-guided biopsy. SUVmax Primary breast 16.4 
lung lesion 4.8 Biopsy results were negative for malignancy. 
 
 
The SUVmax tended to differ across different molecular subtypes, with a 2-fold difference 
between minimum and maximum values (Table 5).  The SUVmax findings of the patients who 
had metastases were analysed against their respective molecular subtypes (on surrogate 
markers). Patients with HER2 disease demonstrated the highest values (SUVmax=20.2) while 
patients with luminal disease demonstrated lower values (SUVmax=10.19).  
 
Table 5: SUV values against molecular subtypes in metastatic disease 
Molecular subtype N minimum maximum median IQR 
Luminal 4 3.4 10.19 4.11 3.54 
HER2 over-expressed 2 3.7 12.99 8.35 9.29 
Triple Negative 7 2.97 14.5 6.2 9.06 
Luminal HER2 positive 2 6 20.2 13.1 14.2 
Luminal HER2 equivocal 6 3.49 10.4 7.75 2.93 
Abbreviations: IQR, inter-quantile range 
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1.8. Discussion 
The study aimed to assess the difference in the sensitivity of 18F-FDG PET/CT and CI in 
detecting metastases in patients with locally advanced invasive ductal carcinoma (IDC) of the 
breast treated at Groote Schuur Hospital. 18F-FDG PET/CT was superior to the selected CI 
(CXR, USG, bone scan) in the detection of distant metastases(p=0.0077), resulting in the 
upstaging of disease in 21.4% of patients from clinical stage IIIa to stage IIIc, and changed 
management in 54 % of patients. Of the 5 suspected metastatic sites that were biopsied, only 
one was positive for malignancy. This indicates the limited specificity of 18F-FDG PET/CT to 
distinguish between malignant and benign lesions. 
The CNP of South Africa recommend the use of  PET/CT in breast cancer in select cases as an 
adjunct to CI when such modalities are equivocal, as well as in disease recurrence for staging.27 
The NCCN guidelines recommend 18F-FDG PET/CT as a category 2B (weak evidence) option 
for  diagnostic staging work-up.. The NCCN also advocates for its use in LABC particularly in 
patients with equivocal or suspicious findings on conventional standard staging modalities.19, 28 
The main reason for not advocating for upfront use of 18F-FDG PET/CT is the lack of data 
showing a clear clinical benefit.  
The existing data comparing 18F-FDG PET/CT and CI modalities has shown the superior 
sensitivity of 18F-FDG PET/CT in the detection of occult metastasis, extra-axillary nodal 
disease, and has the added advantage of being a full-body examination in a single session.3, 12, 
14 However, there is a scarcity of any prospective data from developing countries, where in 
addition to late presentation, infectious diseases remain a big challenge.29 International 
literature has most patients presenting with earlier stages of disease (stage IIB or IIIA),12 in 
comparison to LMIC where more advanced stages (IIIB or IIIc) are the majority.14 This 
prospective study of 42 LABC patients who were simultaneously staged with 18F-FDG PET/CT 
and conventional imaging, found 70% of patients staged as IIIB or IIIC. 
The study aimed to assess the difference in sensitivity in detecting metastases between whole-
body 18F-FDG PET/CT and conventional imaging (CI) in patients with locally advanced 
invasive ductal carcinoma (IDC). Overall, our findings suggest that 18F-FDG PET/CT was able 
to detect more metastases than the selected CI (CXR, USG, bone scan), and resulted in 
upstaging of disease, which was similar to previous studies.3, 9, 12, 14, 30 However, it was not 
possible to determine sensitivity and specificity due to the limited number of patients who 
underwent biopsies as indicated in Table 2. 
The apparent superiority of 18F-FDG PET/CT and CI as a staging modality was in the detection 
of mediastinal lymphadenopathy. In the other common sites of breast metastases (lung 
parenchyma, liver and bone), there was no difference detected between 18F-FDG PET/CT and 
CI. Our data is consistent with the earlier studies conducted by Schirrmeister et al. and Dose et
al. who found that 8F-FDG PET/CT was superior for the detection of distant metastasis,
particularly the presence of mediastinal and thoracic lymph node metastases.9, 30
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18F-FDG PET/CT upstaged the nodal status in 5 patients by detecting internal mammary nodes 
(IMN). This had an impact on the target delineation and field of radiotherapy. Including 
involved IMN in the radiotherapy field has shown a trend towards improved disease-free 
survival, and overall survival. 31, 32 Riegger et al showed in a retrospective study that 18F-FDG 
PET/CT had an impact on both surgical procedures and the delineation of radiotherapy targets 
in breast cancer.32  
Concern regarding the use of 18F-FDG PET/CT in areas where infectious diseases are prevalent 
is an important consideration. In this study, our patients came from communities with high 
Tuberculosis prevalence. Tuberculosis is known to be a PET-avid infectious disease.34, 35 The 
uptake of 18F-FDG in lymph nodes should ideally be confirmed to be metastatic by biopsy, due 
to the known low specificity of the radiopharmaceutical, raising concern for the possibility of 
false positives.3, 10 In accordance with our study protocol, patients with isolated solitary 
metastatic lesions on 18F-FDG PET/CT were subjected to a biopsy for histopathological 
confirmation if considered safe (Figures 1-3). The low positive biopsy results of only 20% was 
in agreement with the known poor specificity of 18F-FDG PET/CT. Histopathological 
confirmation must therefore not be omitted in cases of isolated solitary lesions found on 18F-
FDG PET/CT as these may lead to incorrect upstaging and treatment. There may be a possibility 
of biopsy yielding spurious results in certain cases. Therefore, co-registration of suspected 
lesions on 18F-FDG PET/CT with imaging used in the biopsy is suggested including both 
nuclear physician and the physician performing the directed biopsy for maximal yield. 
18F-FDG PET/CT detected ipsilateral supraclavicular lymphadenopathy in 10 (23.8%) patients, 
which was clinically detected in only 5 (11.9%) patients. All patients with 18F-FDG PET/CT- 
detected ipsilateral supraclavicular lymphadenopathy or isolated mediastinal lymphadenopathy 
had clinically advanced T4-disease (skin ulceration or oedema). There is a risk of super-imposed 
infection in these lesions, and a corresponding inflammatory response in the draining lymph 
nodes. Unlike developed countries, our patients (>60%) commonly present with such advanced 
disease. We would recommend that breast ultrasound, including axilla be extended to the 
supraclavicular areas, to help distinguish between inflammatory and metastatic lymph nodes. 
18F-FDG PET/CT is an important diagnostic tool in the identification of non-regional distant 
metastatic lymphadenopathy in LABC, especially mediastinal, as shown by our study. The non-
regional lymphadenopathy assumes more significance when it is not accompanied by other 
distant metastases. Therefore, the use of 18F-FDG PET/CT in LABC should be routinely used 
in centres with the capability of biopsy of such sites, in order to avoid up-staging of disease.  
The majority of distant metastatic disease (60%) seen on 18F-FDG PET/CT is of the aggressive 
subtype. This is consistent with international studies, where the amount of FDG uptake is 
determined by the presence of glucose metabolism and hypoxia in breast cancer cells.13, 14 In 
the present study, SUVmax values tended to differ across different molecular subtypes. However, 
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confirmation in larger studies with similar use of subtyping via molecular surrogate markers 
should be done.  
The study has highlighted the superiority of 18F-FDG PET/CT over CI in our LABC cohort. 
Clinically this is useful for selection of patients that would derive the most benefit from this 
staging investigation, especially if coupled with access to histologic confirmation of the ‘hot 
spots’ found on 18F-FDG PET/CT. 18F-FDG PET/CT was superior to CI mainly for mediastinal 
lymphadenopathy. Patients with isolated mediastinal lymphadenopathy based on 18F-FDG 
PET/CT warrant further confirmatory investigation before they can be classified as having 
metastatic disease.  
18F-FDG PET/CT has limited specificity in its ability to distinguish between malignant and 
benign lesions, both of which demonstrate increased glucose utilization.12 The low number of 
histological confirmations of all imaging findings by biopsy was one of the main limitations of 
this study. The study was also limited by its design as a single institutional prospective study. 
Most quoted studies used CT scan of the chest and abdomen as a part of CI, whereas we used 
chest X-ray and ultrasound of the abdomen as was the prevailing policy at our institution at the 
time. The addition of CT chest scans has been shown to improve the sensitivity of CI.12, 14 
Although the current study was suitably powered to answer the research question, we 
acknowledge that small sample sizes may lack generalizability due to lack of sufficient 
randomization and stratification. Future research should include larger samples recruited from 
multiple centres. 
1.9. Conclusion 
18F-FDG PET/CT is more accurate than CI for the initial staging of LABC, frequently upstaging 
clinical disease, and requiring modification of loco-regional management. It also provided more 
accuracy in detection of distant metastases. It was most useful in the identification of 
mediastinal lymphadenopathy. It provides the convenience of examining the whole body in a 
single session. The use of 18F-FDG PET/CT in comparison to CI in this study, therefore, showed 
a clinical difference in the evaluation of LABC staging, increasing its utility in this clinical 
group of breast cancer. The use of 18F-FDG PET/CT for breast cancer staging is therefore 
recommended in LABC, with a better accuracy if biopsy of isolated suspected metastatic lesions 
can be performed safely and timeously. Larger multi-centred prospective studies are required 
to ascertain the significance of isolated solitary lesions on 18F-FDG PET/CT. Further research 
into the genetic profile of breast cancer patients and its correlation to quantitative PET/CT 
parameters is warranted. (Words: 4244)   
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Appendices 
1.15. Appendix A: SAJO manuscript guidelines
Original Research Article full structure 
Title: 
• Full title: Specific, descriptive, concise, and comprehensible to readers outside the
field. Max 95 characters (including spaces).
• Tweet for the journal Twitter profile: This sentence/statement will be used on the journal
Twitter profile to promote your published article. Max 101 characters (including
spaces). If you have a Twitter profile, please provide us your Twitter @ name. We will
tag you to the Tweet.
 Abstract: The Abstract should provide the context or background for the study and should 
state the study's purpose, basic procedures (selection of study participants, settings, 
measurements, analytical methods), main findings (giving specific effect sizes and their 
statistical and clinical significance, if possible), and principal conclusions. The Abstract should 
not exceed 250 words. Please minimize the use of abbreviations and do not cite references in 
the abstract. Refer to the relevant article type’s guideline you are submitting for the abstract 
sections. 
Introduction: The Introduction should put the focus of the manuscript into a broader context 
and explain its social and scientific value. Address this to readers who are not experts in this 
field and include a brief review of the key literature. If there are relevant controversies or 
disagreements in the field, they should be mentioned. Conclude with a brief statement of the 
overall aim of the experiments and a comment about whether that aim was achieved. Cite only 
directly pertinent references, and do not include data or conclusions from the work being 
reported. 
Methods: The Methods section should provide clarity about how and why a study was done in 
a particular way. It should provide enough detail for reproduction of the findings. Protocols for 
new methods should be included, but well-established methodological procedures may simply 
be referenced. A full description of the methods should be included in the manuscript itself 
rather than in a supplemental file. Only information that was available at the time the plan or 
protocol for the study was being written must be included; all information obtained during the 
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study belongs in the Results section. If an organization was paid or otherwise contracted to help 
conduct the research (examples include data collection and management), then this should be 
detailed in the methods. 
The methods section should include: 
• The selection and description of participants or description of materials.
• The aim, design and setting of the study.
• The description of the processes, interventions and comparisons. Generic drug names
should generally be used. When proprietary brands are used in research, include the
brand names in parentheses.
• The type of statistical analysis used, including a power calculation if appropriate.
The Methods section should include a statement indicating that the research was approved or 
exempted from the need for review by the responsible review committee (institutional or 
national). If no formal ethics committee is available, a statement indicating that the research 
was conducted according to the principles of the Declaration of Helsinki should be included. 
Results: Present your results in logical sequence in the text, tables, and figures, giving the main 
or most important findings first. Do not repeat all the data in the tables or figures in the text; 
emphasize or summarize only the most important observations. Provide data on all primary and 
secondary outcomes identified in the Methods Section. Give numeric results not only as 
derivatives (for example, percentages) but also as the absolute numbers from which the 
derivatives were calculated, and specify the statistical significance attached to them, if any. 
Restrict tables and figures to those needed to explain the argument of the paper and to assess 
supporting data. Use graphs as an alternative to tables with many entries; do not duplicate data 
in graphs and tables. Avoid nontechnical uses of technical terms in statistics, such as “random” 
(which implies a randomizing device), “normal,” “significant,” “correlations,” and 
“sample.” Separate reporting of data by demographic variables, such as age and sex, facilitate 
pooling of data for subgroups across studies and should be routine, unless there are compelling 
reasons not to stratify reporting, which should be explained. 
 Conclusion: It is useful to begin the discussion by brieﬂy summarizing the main ﬁndings, and 
explore possible mechanisms or explanations for these ﬁndings. Emphasize the new and 
important aspects of your study and put your findings in the context of the totality of the relevant 
evidence. State the limitations of your study, and explore the implications of your ﬁndings for 
future research and for clinical practice or policy. Discuss the influence or association of 
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variables, such as sex and/or gender, on your findings, where appropriate, and the limitations 
of the data. Do not repeat in detail data or other information given in other parts of the 
manuscript, such as in the Introduction or the Results section. Link the conclusions with the 
goals of the study but avoid unqualified statements and conclusions not adequately supported 
by the data. In particular, distinguish between clinical and statistical significance, and avoid 
making statements on economic benefits and costs unless the manuscript includes the 
appropriate economic data and analyses. Avoid claiming priority or alluding to work that has 
not been completed. State new hypotheses, when warranted and label them clearly. 
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